| Santhera Pharmaceuticals (Schweiz) AG - Qinlock 50 mg, Tabletten | | 68199 | | 01 | | Qinlock 50 mg | | Tabletten | | L01EX19 | | Ripretinib | | 07.10.2021 | | |
| | Composition | | ripretinibum 50 mg, hypromellosi acetas succinas, cellulosum microcristallinum, lactosum monohydricum 179 mg, crospovidonum, silica colloidalis anhydrica, magnesii stearas, pro compresso. | | Packungsbestandteile | | Tablets | | | | | Active Agent | Dose |
|---|
| Ripretinibum | 50 mg |
| | BAG: Active Agent | Dose |
|---|
| Ripretinibum | 50 mg |
| | | | Inactive agents | Dose |
|---|
| Cellulosum Microcristallinum | | | Crospovidonum | | | Hypromellosi Acetas Succinas | | | Lactose Monohydrate | 179 mg | | Magnesii Stearas | | | Pro Compresso | | | Silica Colloidalis Anhydrica | |
| |
| |
|
